Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value – Scopus BioPharma

Skip to content

Home
About
Team
Programs
Media
News and Events
Investors
Contact

Menu

Home
About
Team
Programs
Media
News and Events
Investors
Contact

Scopus BioPharma Completes Recapitalization Designed to Enhance Shareholder Value (10.18.22) FINAL

Home
About
Team
Programs
Media
News and Events
Investors
Contact

Menu

Home
About
Team
Programs
Media
News and Events
Investors
Contact

Contact

Contact

About

Overview
Team Background
Public Healthcare

Overview
Team Background
Public Healthcare

Team

Leadership
Board of Directors
Scientific Advisory Board
Senior Advisors

Leadership
Board of Directors
Scientific Advisory Board
Senior Advisors

Programs

Overview
Pipeline
Strategic Partners
Drug Candidates
CO-sTiRNA™
MRI-1867
Additional R&D Programs
Scientific Publications

Overview
Pipeline
Strategic Partners
Drug Candidates
CO-sTiRNA™
MRI-1867
Additional R&D Programs
Scientific Publications

Media

Media

Media

News and Events

Press Releases
News
Events
Presentations

Press Releases
News
Events
Presentations

Investors

Company Information
News and Events
Presentations
SEC Filings
Corporate Governance
Stock Data
Research Coverage

Company Information
News and Events
Presentations
SEC Filings
Corporate Governance
Stock Data
Research Coverage

Contact

Contact

© 2023 Scopus BioPharma. All rights reserved | Privacy Policy | Cookies Policy